Business

India’s Pharma Market Grows 8.4% In FY25; Boosted By Chronic Therapies & New Drug Launches

India’s pharma market grew by 8.4% during the financial year 2024-25, propelled by strong performance in key chronic therapy areas, according to market research firm Pharmarack.

The cardiac segment led with a 10.8% value growth, followed closely by gastrointestinal (10.2%) and anti-diabetic (8%) therapies.

Together, these three therapy areas contributed 34% of the total pharma market sales, helping push the industry’s overall turnover to over ₹2.25 trillion.

Top-Selling Drugs Led By Chronic Treatments

Despite the chronic therapies dominating in growth, GSK’s antibiotic Augmentin emerged as the top-selling drug of FY25 with ₹816 crore in sales.

USV’s Glycomet GP, an anti-diabetic medication, followed closely with ₹803 crore in sales.

While value growth was strong, unit sales in the domestic market recorded a modest 1.2% increase, indicating that growth was largely price-driven.

Empagliflozin Patent Expiry Sparks Price War

March 2025 saw a significant market shift with the diabetes molecule empagliflozin going off-patent.

Within a month, 86 brands from 19 companies launched empagliflozin-based products. Sheetal Sapale, vice-president (commercial) at Pharmarack, noted a steep price drop—around 85%—with prices falling from ₹60-70 per tablet to just ₹5-15.

Despite a rise in volume, the value declined due to this price erosion.

Anti-Obesity Market Gets Boost From Mounjaro

The launch of Eli Lilly’s Mounjaro (tirzepatide) in March 2025 added momentum to India’s emerging anti-obesity market.

In just one month, Mounjaro contributed ₹1.4 crore to the segment’s ₹576 crore moving annual turnover. Semaglutide, another GLP-1-based drug, accounted for 69% of this total over the previous 12 months.

Double-Digit Growth For Leading Companies

Several leading pharma companies posted strong domestic value growth in March 2025. Sun Pharma (14.9%), Torrent Pharma (14.7%), Intas (12.8%), and Zydus (10.8%) all recorded double-digit growth.

Overall, the pharma market witnessed a 7.5% value growth and 1.8% unit growth in March alone, reflecting broad-based strength across segments.

Also Read: India’s $2.7 Billion PLI Scheme Set To Boost Local Electronics Manufacturing

Purnima Mishra

Recent Posts

CMD Upendrra Rai Pays Tribute To Gopal Das Neeraj At Delhi’s ‘Karwan Geeton Ka… Neeraj’ Programme

Bharat Express CMD Upendrra Rai paid tribute to poet Gopal Das Neeraj at a Delhi…

6 hours ago

Union Minister SP Singh Baghel, CMD Upendrra Rai Attend ‘Karwan Geeton Ka… Neeraj’ In Delhi

Union Minister of State Prof SP Singh Baghel and Bharat Express CMD Upendrra Rai attended…

6 hours ago

Kuldeep Yadav’s Earns Impact Player Of The Series Honour In West Indies ODIs

Kuldeep Yadav was named Impact Player of the Series after claiming seven wickets and helping…

7 hours ago

Dr Rajeshwar Singh Participates In Provincial Teachers’ Dignity Conference In Presence Of CM Yogi Adityanath

Dr Rajeshwar Singh joined Uttar Pradesh teachers at a conference attended by CM Yogi Adityanath,…

8 hours ago

Indore’s Grand Journalism Festival Concludes With Major Participation From Bharat Express

The 18th Indian Journalism Festival concluded in Indore after three days of discussions on Gen-Z,…

9 hours ago

Isabgol For Constipation: Know The Right Way To Take It

Isabgol can ease constipation and support digestion. Know the right dose, timing and method to…

9 hours ago